China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Large Growth in Short Interest

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 7,347,822 shares, a growth of 115.5% from the January 15th total of 3,408,880 shares. Currently, 794.4% of the shares of the company are sold short. Based on an average daily volume of 35,892,593 shares, the short-interest ratio is currently 0.2 days. Based on an average daily volume of 35,892,593 shares, the short-interest ratio is currently 0.2 days. Currently, 794.4% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Institutional Trading of China SXT Pharmaceuticals

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC increased its position in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) by 107.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,983 shares of the company’s stock after acquiring an additional 15,013 shares during the period. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 at the end of the most recent quarter. Institutional investors and hedge funds own 5.02% of the company’s stock.

China SXT Pharmaceuticals Trading Down 0.8%

Shares of NASDAQ SXTC opened at $2.61 on Friday. The firm has a 50-day simple moving average of $115.66 and a 200-day simple moving average of $189.23. China SXT Pharmaceuticals has a 52 week low of $2.34 and a 52 week high of $1,176.00.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.